TMCnet News
Courtagen Continues Menu Expansion with Launch of New Spotlight™ Gene Tests for Neuromuscular DisordersCourtagen Life Sciences, Inc., an innovative molecular endocannabinoid platform and information company, announced today that it has launched 10 new gene panels in its Spotlight line of tests. The tests will expand the company's Spotlight menu in neurology and endocrinology, and adds to the selection of tests currently available for epilepsy, developmental delay, endocrinology, and mitochondrial disease. "We are happy to offer another expansion to our test menu in just a month since our last announcement," stated Brian McKernan, CEO of Courtagen Life Sciences. "Our rapid development engine enables Courtagen to address the testing needs of our ordering physicians and institutions quickly. We expect to significantly expand our test offerings over the course of 2017." The new Spotlight tests will primarily address neuromuscular disorders, such as congenital myasthenia, hereditary spastic paraplegia, congenital and limb-girdle muscular dstrophy, and myopathies, and one new endocrine disorder test for Bardet-Biedl syndrome. To learn more, visit Facebook, Twitter, and Instagram. Follow on social media with hashtags #Courtagen
About Courtagen Life Sciences, Inc. View source version on businesswire.com: http://www.businesswire.com/news/home/20170301005979/en/ |